News from veloxis pharmaceuticals a/s A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 12, 2019, 15:11 ET Notice to Convene Annual General Meeting 2019

The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the annual general meeting in the Company ...


Feb 27, 2019, 13:44 ET Veloxis Pharmaceuticals Releases Annual Report for 2018

Veloxis Pharmaceuticals A/S (OMX: VELO) today releases its Annual Report for the financial year 2018. A complete copy of Veloxis's Annual Report for...


Jun 04, 2018, 11:52 ET Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation

Veloxis Pharmaceuticals A/S is pleased to announce an ongoing partnership with the American Society of Transplant Surgeons (ASTS) to support the...


Apr 20, 2018, 08:14 ET FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®

Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's...


Apr 13, 2018, 08:24 ET Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018

Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today, all proposals from the Board of Directors were adopted, including ...


Apr 03, 2018, 10:04 ET Veloxis Appoints Morten Marott as Chief Financial Officer

Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten Marott is joining the company as its new Chief Financial Officer. Mr. Marott has...


Jun 06, 2017, 15:01 ET Veloxis Pharmaceuticals A/S Announces Agreement for Taiba Healthcare to Commercialize Envarsus XR in the Middle East and North Africa Region

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that its US subsidiary, Veloxis Pharmaceuticals, Inc., has entered into an exclusive license, ...


Jun 06, 2017, 14:59 ET Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR® in Canada

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that its U.S. subsidiary, Veloxis Pharmaceuticals, Inc., and Endo Ventures Limited have...


Jun 06, 2017, 12:57 ET Veloxis Pharmaceuticals A/S Announces Agreement with Chiesi Farmaceutici S.p.A. to Commercialize Envarsus XR in China

Veloxis Pharmaceuticals A/S today announced that its U.S. subsidiary, Veloxis Pharmaceuticals, Inc., has entered into an exclusive license, supply...


Dec 10, 2015, 04:32 ET Veloxis Announces Change In Management

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in...


Oct 14, 2015, 03:00 ET Veloxis Establishes Sponsored Level 1 ADR Program in U.S.

Veloxis Pharmaceuticals A/S (OMX: VELO) today announces the establishment of a sponsored Level 1 American depositary receipt (ADR) program in the U.S....


Sep 21, 2015, 08:15 ET Veloxis Announces Publication of Phase III-b STRATO Study of Envarsus® XR Demonstrating Reduction in Hand Tremors Compared to Twice-Daily Tacrolimus in Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) is announcing the publication of the Phase IIIb Switching STudy of Kidney TRansplant PAtients to LCP-TacrO...


Sep 10, 2015, 08:15 ET Envarsus® XR Data to be Presented at European Society of Transplantation

Veloxis Pharmaceuticals A/S (OMX: VELO) announced that the full data set of the ASTCOFF (A STeady-state Pharmacokinetic COmparison Of all Tacrolimus...


Aug 14, 2015, 04:56 ET Veloxis Pharmaceuticals Envarsus® XR Granted Orphan Drug Status by U.S. Food and Drug Administration for Kidney Transplant Rejection Prophylaxis

Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration...


Jul 10, 2015, 03:38 ET Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced U.S. Food and Drug Administration (FDA) approval of Envarsus® XR (tacrolimus extended-release ...


Jun 24, 2015, 11:30 ET Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced top-line results of the ASTCOFF study, A STeady-state Pharmacokinetic COmparison Of all...


Jun 12, 2015, 02:06 ET U.S. District Court Rules in Veloxis Litigation

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the U.S. District Court for the District of Columbia ruled in favor of the U.S. Food and ...


May 04, 2015, 07:00 ET Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that once-daily Envarsus® XR (tacrolimus extended-release tablets), an investigational new...


Mar 03, 2015, 09:47 ET Veloxis Pharmaceuticals publishes Annual Report 2014

Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2014. The ...


Jan 14, 2015, 02:32 ET U.S. District Court Sets Briefing Schedule in Veloxis Litigation

Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that the U.S. District Court for the District of Columbia has set a briefing...


Jan 13, 2015, 03:05 ET Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision

Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that it has received notice from the U.S. Food and Drug Administration (FDA)...


Dec 16, 2014, 05:38 ET Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR

Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that it has filed an action in federal district court for the District of Columbia against...


Nov 17, 2014, 08:53 ET Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of the Phase III study (Study 3002) of once-daily Envarsus® XR demonstrating...


Oct 31, 2014, 07:16 ET Veloxis announces tentative approval of Envarsus® XR

Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of...


Jul 28, 2014, 02:30 ET Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients

Veloxis Pharmaceuticals A/S (OMX: VELO) and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing...